A Phase 2 study demonstrated the accuracy of lung cancer gene panel testing using cytological specimens, with a success rate of 100% and sufficient yield for analysis. The extracted nucleic acid quality was also adequate for panel analysis, enabling the detection of gene mutations in 68.1% of cases.
A study analyzing surgical tissue samples from patients with stage IIIA NSCLC found that high AKT expression and activated dendritic cells were associated with lower progression-free survival and overall survival. The immune expression signature identified could help follow-up and therapeutic management of high-risk patients.
Combining sotorasib with pembrolizumab or atezolizumab demonstrated durable clinical activity, lower treatment-related adverse events, and improved overall survival in patients with advanced KRAS p.G12C NSCLC. The study showed a higher incidence of grade 3-4 adverse events initially, but these effects may be mitigated by dose reduction.
The NELSON Trial demonstrated a 24% reduction in lung cancer mortality with low-dose CT screening, compared to the 20% found in the NLST. The new protocol used in NELSON showed improved sensitivity for early-stage cancers, increasing the benefits of lung cancer screening while reducing unnecessary follow-up procedures.
A recent study found that younger patients with lung cancer are more likely to be diagnosed at later stages, highlighting the need for strategies to increase early detection among younger adults. In contrast, older patients have seen improvements in earlier stage diagnoses since the onset of lung cancer screening.
Research presented at the IASLC World Conference on Lung Cancer 2022 found that increased utilization of Stereotactic Body Radiotherapy (SBRT) has decreased treatment disparities for early-stage non-small cell lung cancer (NSCLC). The study showed a significant increase in the proportion of patients receiving definitive treatment, with...
The IASLC Early Detection and Screening Committee report outlines the challenges of implementing lung cancer screening in low- and middle-income countries. The committee emphasizes the need for evidence-based guidelines, considering regional specificities and population-specific risk factors.
A budget impact analysis shows that implementing the NELSON screening model in 28 European countries could prevent over 18,000 premature lung cancer deaths. The model estimates a total budget impact of approximately €937 million if half of the eligible population is screened.
A phase 3 trial showed sugemalimab improved progression-free survival (PFS) by 69% compared to placebo, with a median PFS of 10.5 months. Overall survival (OS) data also suggested a trend towards benefit favoring sugemalimab.
A study presented at the IASLC World Conference on Lung Cancer 2022 found four molecular subtypes of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping, each with distinct clinical characteristics and responses to treatment.
Researchers found that second primary lung cancer occurs in approximately 4% of lung cancer patients, with a higher rate of up to 8% among those undergoing surgery for early-stage disease. The study also revealed variations in incidence rates by treatment type and stage.
A new study published in the Journal of Thoracic Oncology found that cytisine, a plant-based alkaloid, is a safe and effective smoking cessation therapy. The study showed a 32.1% quit rate for participants taking cytisine compared to 7.3% for those receiving a placebo.
A new study found that COVID-19 vaccines are safe and effective for patients treated for lung cancer with immune checkpoint inhibitors. However, the vaccine's immunogenicity was lower in these patients, raising concerns that require further evaluation.
The COVID-19 pandemic significantly impacted lung cancer clinical trial enrollment, with a 14% decline between 2019 and 2020. Patient-specific challenges included fear of infection, transportation issues, and willingness to visit sites.
A recent study by TERAVOLT identified seven major determinants of death from SARS-CoV-2 infection in patients with thoracic malignancies, including poor ECOG-PS and laboratory confirmed COVID-19 diagnosis. The study found a high all-cause case fatality rate of 24.2% among patients with COVID-19 and thoracic cancer.
A meta-analysis of published research found that patients with lung cancer who quit smoking after diagnosis have significantly improved overall survival. The study suggests treating physicians should educate patients about the benefits of quitting and provide necessary support.
A new study found that SARS-CoV2 vaccines are safe and effective in patients with thoracic cancer, with an 88% immunization rate after a third dose. The study also showed that older age, chemotherapy, and corticosteroid treatment were associated with lower immunization rates.
Researchers found that pre-treatment circulating tumor DNA (ctDNA) levels can accurately predict long-term survival in non-small cell lung cancer (NSCLC) patients. Patients with low ctDNA levels had significantly improved progression-free survival and overall survival compared to those with high levels.
A new study suggests that age does not negatively impact on survival benefit from immune checkpoint inhibitors in elderly patients with stage IV NSCLC. Patients aged 75 and older showed a significant survival benefit from ICIs compared to younger patients.
According to a survey, nearly two-thirds of thoracic oncologists adopted telehealth tools for the first time during the pandemic. The top advantages were continuity of care and maintaining patient contact, while barriers included lack of resources and regulatory limitations.
Research presented at the IASLC 2021 World Conference on Lung Cancer found that neoadjuvant cisplatin and pemetrexed plus atezolizumab followed by surgical resection and maintenance atezolizumab met safety criteria for patients with resectable pleural mesothelioma. Sixty percent of eligible patients proceeded to maintenance therapy.
A meta-analysis of the UKLS trial and nine previous trials found that low-dose CT (LDCT) screening for lung cancer reduces mortality by 16%, with a stronger benefit seen in the three to six years after randomization. This evidence supports the implementation of long-term lung cancer screening programs internationally.
A study of 2,804 patients found significant variability in access to care for malignant pleural mesothelioma treatment. Patients who underwent surgery had better survival outcomes, with a positive association between multimodality treatment and income levels.
A recent study found that patients with lung cancer are more likely to feel anxious and experience treatment delays due to the COVID-19 pandemic. The research, which analyzed data from 548 patients in Mexico, also discovered that depression and stress were associated with longer delays in treatment.
The IASLC molecular subcommittee has accumulated molecular biomarker data to complement TNM-based prognostication in lung cancer. The dataset includes 64,434 cases from 2010-2019 and 14 countries, with EGFR being the most common biomarker.
Treatment with atezolizumab plus carboplatin and pemetrexed was safe and yielded promising brain progression-free survival rates of 60% in patients with nonsquamous non-small cell lung cancer with untreated brain metastases. The combination also showed systemic responses in 47.5% of patients.
A study analyzed open and closed insurance claims to assess practice behavior changes after durvalumab approval. The results showed a low rate of durvalumab utilization, with higher rates in patients over 65 and treated in the Midwest.
A mixed-methods survey of US-based oncology clinicians reveals disparities in biomarker testing use, with academic clinicians more likely to use it. Clinicians express need for education on financial resources, practical applications, and coordinating multidisciplinary care.
A multicenter clinical trial tested the use of lurbinectedin in patients with small cell lung cancer (SCLC), which did not meet its primary end point of overall survival. However, the combination of lurbinectedin and doxorubicin was found to be active in patients with SCLC after one prior platinum-based chemotherapy.
Air pollution attributed to lung cancer ranks highest in Balkan countries and Poland, particularly among those aged 50-69. The top five countries are Serbia, Montenegro, North Macedonia, Bosnia/Herzegovina, and Poland.
The COVID-19 pandemic led to a significant decline in lung cancer clinical trial enrollment, with 43% fewer participants enrolling between 2019 and 2020. Researchers identified several barriers, including patient concerns about infection and transportation, as well as institutional challenges such as closures and staff availability.
The IMpower010 trial found significant disease-free survival improvement in patients with resected stage II-IIIA non-small cell lung cancer treated with atezolizumab. The study showed a benefit across different disease stages, surgery types, and chemotherapy regimens.
The Phase III POSEIDON trial demonstrated a statistically significant improvement in progression-free survival and overall survival for patients with metastatic non-small cell lung cancer (mNSCLC) treated with chemotherapy plus durvalumab and tremelimumab. Durvalumab combined with tremelimumab and chemotherapy reduced the risk of death...
A recent case study from a Barcelona hospital found that nearly 20% of patients with malignant pleural mesothelioma contracted COVID-19 during the pandemic. The study revealed a 75% mortality rate among these patients, highlighting the severity of the impact of COVID-19 on this vulnerable population.
Dr. Michael Boyer is the chief clinical officer at The Lighthouse Chris O'Brien comprehensive cancer center in Sydney, Australia. He has been recognized with the Adi F. Gazdar IASLC Merit Award for his pioneering work in molecular pathology and dedication to lung cancer research.
Recent studies published in the Journal of Thoracic Oncology have found that rovalpituzumab tesirine is not effective against small cell lung cancer, despite initial promise shown in early clinical trials. The therapy has been plagued by high rates of side effects and lack of survival benefits.
A study published in Journal of Thoracic Oncology found that low-dose computed tomography (LDCT) screening for primary lung cancer is associated with a lower risk of developing brain metastases. Researchers identified 1502 participants diagnosed with lung cancer between 2002 and 2009, where LDCT screening was detected versus other meth...
A new study published in the Journal of Thoracic Oncology found that using traditional methods like BMI can misclassify obesity as a non-risk factor for lung cancer. The researchers measured visceral fat index through CT scans and found a clear correlation between central obesity and poor lung cancer outcomes.
The study, led by Caicun Zhou, found that sintilimab-gemcitabine/platinum improved progression-free survival over placebo-gemcitabine/platinum. The results demonstrated a 46.4% reduction in disease progression or death risk.
The IASLC Molecular Database Project seeks to accelerate understanding of lung cancer biology, clinical care, and global scale. It aims to provide a platform for deeper, broader understanding of molecular testing and targeted therapy.
A new lymph node collection kit has been shown to improve long-term survival after curative-intent lung cancer surgery. The kit helps surgeons attain complete resection by improving pathologic nodal evaluation, leading to a significant increase in R0 resections and reduction in non-examination of lymph nodes.
Patients with non-small cell lung cancer who enrolled in a phase III early-stage trial showed a high rate of smoking reduction and cessation following study entry. Smoking rates were significantly lower among never-smokers, leading to improved overall survival compared to smokers.
The phase III CROWN study showed that lorlatinib significantly improved progression-free survival compared to crizotinib in patients with previously untreated advanced ALK-positive NSCLC. Patient-reported outcomes also indicated comparable time to treatment deterioration for lung cancer symptoms between the two treatments.
The LCMC3 study showed that neoadjuvant atezolizumab was well tolerated and met its primary endpoint, achieving a major pathologic response rate of 21% in patients without EGFR/ALK mutations. The therapy also showed high complete resection rates and low perioperative morbidity and mortality.
A host immune classifier test may help guide immunotherapy treatment decisions for patients with newly diagnosed non-small cell lung cancer. The test, which measures inflammation in the body, is associated with longer overall survival and better treatment response.
Researchers analyzed mRNA expression levels of molecular markers ERCC1 and thymidylate synthase in patients with resected stage II-III non-small cell lung cancer. The study found no correlation between these markers and overall survival, contradicting previous hopes for a personalized chemotherapy approach.
A nationwide lung cancer LDCT screening study found the effectiveness of low-dose computed tomography (LDCT) screening in a pre-defined, never-smoker population. The study revealed that family history significantly increased lung cancer risk, and most participants had stage 0 or 1 disease.
The Checkpoint Blockade for Inhibition of Relapsed Mesothelioma (CONFIRM) study demonstrated that nivolumab significantly improves overall and progression-free survival in patients with relapsed malignant mesothelioma. The treatment also showed a consistent safety profile without new adverse effects.
Two ADAURA analyses presented at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer (WCLC) Singapore support the use of Osimertinib as a new treatment strategy for patients with surgically resected, Stage IB to IIIA non-small cell lung cancer. The data show significant disease-free surviva...
Researchers investigating lung cancer treatment during the pandemic found that patients with lung cancer experience higher levels of psychological distress and anxiety about accessing care. The study also revealed that patient advocacy organizations face challenges in providing support due to decreased funding.